from the Quarterly:
Study review and next steps
As outlined in the recent announcement, the vehicle response seen with all US sites was unusually
two to four times higher than that seen in Australia, for both inflammatory and non-inflammatory
lesion reduction measures respectively. The Company is confident that the execution of the study
protocol was consistent across geographies and within geographies, whereas the manufacturing and
Phase 2 study supply was the key differences between the geographies. Botanix is actively
investigating the reasons for this unusual US response and is working with external experts in both
clinical management and manufacturing to review the study conduct, operations and materials.
- Forums
- ASX - By Stock
- Bot Chart
from the Quarterly:Study review and next stepsAs outlined in the...
-
- There are more pages in this discussion • 11,018 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BOT (ASX) to my watchlist
(20min delay)
|
|||||
Last
37.0¢ |
Change
-0.010(2.63%) |
Mkt cap ! $669.7M |
Open | High | Low | Value | Volume |
37.5¢ | 37.5¢ | 35.0¢ | $2.714M | 7.459M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
15 | 196218 | 37.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
37.5¢ | 481641 | 15 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
11 | 142958 | 0.370 |
13 | 307297 | 0.365 |
13 | 410915 | 0.360 |
11 | 926849 | 0.355 |
11 | 831727 | 0.350 |
Price($) | Vol. | No. |
---|---|---|
0.375 | 464711 | 12 |
0.380 | 516346 | 17 |
0.385 | 207424 | 8 |
0.390 | 723886 | 12 |
0.395 | 381136 | 11 |
Last trade - 14.23pm 15/07/2024 (20 minute delay) ? |
Featured News
BOT (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online